Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

MedMira adds three new rapid vertical flow tests to Multiplo product line

MedMira adds three new rapid vertical flow tests to Multiplo product line

EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Scientist develops highly accurate device for diagnosing fatal lung disease

Scientist develops highly accurate device for diagnosing fatal lung disease

Researchers collaborate to tackle rare diseases

Researchers collaborate to tackle rare diseases

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

A*STAR, Roche partner to identify novel drug targets for cancer treatment

A*STAR, Roche partner to identify novel drug targets for cancer treatment

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

OHS performs clinical drug trial to reduce cholesterol levels with just one injection

OHS performs clinical drug trial to reduce cholesterol levels with just one injection

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.